However, recently it has been reported that GREB1 levels are elevated in the tumors of castration-resistant prostate cancer patients who have progressed undergoing enzalutamide treatment, providing evidence through xenograft models that GREB1 is required for in vivo enzalutamide resistance [27]. This evidence concerns the gene GREB1 and prostate cancer.